VENTRICULAR ARRHYTHMIAS IN PATIENTS MANAGED WITH IBRUTINIB FOR CANCER IMMUNOTHERAPY
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(18)30820-9
Abstract: Ibrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor associated with dramatic improvements in outcomes of various B-cell hematologic malignancies and is now standard therapy. However, Ibrutinib is associated with a >4-fold increased risk of… read more here.
Keywords: managed ibrutinib; patients managed; arrhythmias patients; ventricular arrhythmias ... See more keywords